Indeed, PTEN downregulation and AKT increased phosphorylation were shown to be associated with increased CDK2/cyclin E2 expression in breast cancer cell lines resistant to CDKi, rendering PI3K inhibitors (capable of downregulating cyclin E2) an attractive partner to overcome resistance to CDKi (89). The gene discussed is CCNE2; the disease is breast cancer.